A Form 4 filed with the SEC on September 8, 2026, reported that Gordon Hunter, a director of Littelfuse Inc /DE (NASDAQ:LFUS), acquired a total of 8 shares of common stock on September 3, 2026, through two separate dividend-related transactions.
Kristina A. Cerniglia, a director at Littelfuse Inc /DE (NASDAQ:LFUS), filed a statement of changes in beneficial ownership on September 8, 2026, disclosing a common stock acquisition dated September 3, 2026.
Sohail Prasad, President and CEO of Destiny Tech100 Inc., filed a Form 4 on September 8, 2026, disclosing three open-market purchases of common stock totaling 56,000 shares between September 1 and September 3, 2026.
A NASDAQ-listed biotechnology company is trading sharply lower today despite raising its full-year guidance following a strong quarter, an outcome that would typically be read as good news for the stock. BioCryst Pharmaceuticals (NASDAQ:BCRX) is underperforming the broader healthcare sector even after reporting a …
A NASDAQ-listed clinical-stage biotechnology company is trading lower today despite presenting durable clinical data for its lead gene-editing program, a reaction that runs counter to what would typically be viewed as positive news. Beam Therapeutics (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302, its …
Compass Pathways (NASDAQ:CMPS) shares are rallying alongside a broad, sector-wide surge in biotechnology stocks, with peers including Roivant Sciences (NASDAQ:ROIV), up 17.7%, and Soleno Therapeutics (NASDAQ:SLNC), up 10%, also posting sharp gains despite limited company-specific news across the sector today. Compass is a clinical-stage …
Dyne Therapeutics (NASDAQ:DYN) shares are plunging after peer Novartis (NYSE:NVS) reported that its Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 failed to hit statistical significance on its primary endpoint of video hand opening time versus placebo. Dyne is a clinical-stage …
Enovis (NYSE:ENOV) shares surged after the company announced a binding offer to acquire eCential Robotics for €155 million. Insider buying momentum has continued alongside the deal news, with CEO Damien McDonald and Chief Administrative Officer Oliver Engert making repeated open-market purchases in recent weeks, …
A NASDAQ-listed clinical-stage biopharmaceutical company is trading sharply lower today despite reporting positive clinical data for both of its lead oral obesity candidates, a reaction that runs counter to what would typically be viewed as positive news. Structure Therapeutics (NASDAQ:GPCR) reported that aleniglipron's 72-week …
Novartis (NYSE:NVS) shares are plunging roughly 14%, marking one of the stock's worst single-day declines on record, after the company disclosed that del-desiran (delpacibart etedirsen) failed to meet its primary endpoint in the Phase 3 HARBOR trial for myotonic dystrophy type 1. This marks …